Figure 24.
Synergistic cancer treatment based on PTT. (a) Chemo-PTT. Au@PAA Janus nanoparticles are used as the templates to grow a mSiO2 shell and Au branches, which are separately modified with methoxy-poly(ethylene glycol)-thiol (mPEG-SH) and lactobionic acid (LA). Left: schematic illustrating the octopus-type PEG-Au-PAA/mSiO2-LA Janus nanoparticle. Right: release profiles of the DOX-loaded Janus nanoparticles under different treatments. Reprinted with permission from ref (718). Copyright 2016 Wiley-VCH. (b) Gene-PTT. Peptide lipid and sucrose laurate are used to coat CNTs to form bifunctional delivery systems (denoted as CNT-PS). Left: schematic showing the temperature-sensitive CNT-PS/siRNA nanoparticle for synergistic PTT and GT. Right: qualitative analysis by fluorescence microscopy of apoptotic cells under the combined treatment. Reprinted with permission from ref (313). Copyright 2021 American Chemical Society. (c) Immuno-PTT. Left: schematic illustrating SPNE-mediated multicellular engagement, immune activation, and NIR-II photothermal effects. Middle and right: confocal laser scanning microscopy (CLSM) images of 4T1 cells, T cells, and DCs cocultured with uncoated semiconducting polymer nanoparticles SPNU (middle) or SPNE (right). 4T1 cells and DCs are labeled with DiI (red) and DiO (green) molecular probes, respectively. DCs are stained with phycoerythrin anti-CD80 antibody and fluorescein isothiocyanate anti-CD86 antibody (yellow). Reprinted with permission from ref (703). Copyright 2021 Wiley-VCH.